Pulmonary manifestations of inflammatory bowel disease

Majewski, Sebastian; Piotrowski, Wojciech J.

doi:10.5114/aoms.2015.56343

Cited by 62 publications

(38 citation statements)

References 121 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IBD is known to have extra-intestinal manifestations, including in the lungs ( 8 ). The pulmonary complications of IBD include inflammation of the small and large airways, pulmonary parenchymal disease, serositis, and pulmonary embolism ( 9 ).…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Alveolar Proteinosis with Ulcerative Colitis

et al. 2018

View full text Add to dashboard Cite

A 65-year-old Japanese man was referred to our hospital for the further assessment of cough and dyspnea. He had a history of ulcerative colitis for which he was receiving treatment. Chest computed tomography showed a crazy-paving pattern. His bronchoalveolar lavage fluid had a milky appearance, and a transbronchial lung biopsy specimen revealed acellular periodic acid-Schiff stain-positive bodies. The serum anti-granulocyte macrophage-colony stimulating factor (GM-CSF) antibody titer was elevated. The diagnosis was autoimmune pulmonary alveolar proteinosis (PAP). There are few reports of autoimmune PAP in patients with ulcerative colitis. Some reports suggest that PAP and inflammatory bowel disease might have a common pathogenesis involving the anti-GM-CSF antibody.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary Alveolar Proteinosis with Ulcerative Colitis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, these drugs or IBD itself were known to cause ILD, especially lymphocyte infiltration or fibrosis on interstitial tissue of lung [18]. Remarkably, almost all these case series did not develop ILD until induction of anti-TNFα agent, despite long-term administration of 5-ASA or AZA, and this fact indicates that anti-TNFα might have some pathogenic effect of developing IDL or exacerbating latent ILD lesions caused by other drugs of IBD or IBD itself.…”

Section: Discussionmentioning

confidence: 99%

A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα

et al. 2019

View full text Add to dashboard Cite

A 40-year-old man with refractory ulcerative colitis (UC) was treated with tumor necrosis factor α inhibitor (anti-TNFα), infliximab. One month later, the chest computed tomography and laboratory test showed noninfectious interstitial lung disease (ILD) and elevation of serum Krebs von den Lungen-6 (KL-6). Fortunately, ILD disappeared after the discontinuation with anti-TNFα. Two and a half years after his first UC treatment, he was treated again with another anti-TNFα, adalimumab, for relapse and he had a second ILD. This course suggested anti-TNFα induced ILD. The characteristics of anti-TNFα-induced ILD in inflammatory bowel disease (IBD) are not well understood. We summarized and investigated the characteristics of such patients based on a literature review including 15 cases. It suggested that anti-TNFα-induced ILD in IBD might be rare and tends to have a better outcome compared with ILD in rheumatoid arthritis.

show abstract

“…Częstość występowania manifestacji płucnych w przebiegu NChZJ wynosi od 20 do nawet 40% [7,12,14]. Rzadziej dochodzi do powikłań płucnych po stosowanej farmakoterapii, najczęściej o charakterze infekcyjnym, ale także z powodu nadwrażliwości na stosowane leki.…”

Section: Dyskusjaunclassified

Pulmonary Manifestations of Crohn’s Disease or Chronic Pharmacotherapy Complications? – Case Report

Rakoczy

Liczek²,

Panek³

et al. 2020

Wiad Lek

View full text Add to dashboard Cite

Pareneteral manifestations of Crohn’s disease (ChLC), apart from the most common skin and joint symptoms include also complications from the respiratory system. In addition chronic pharmacotherapy of ChLC, especially 5-aminosalicylic acid or anti-TNF- α drugs, is associated with possible pulmonologic side effects, sometimes difficult to differentiate. In this study, we describe a patient with ChLC, with a history of pneumocystic pneumonia, who was diagnosed with exfoliative institial pneumonitis as a result of chronic use of mesalazine. This disease is characterized by accumulation of alveolar macrophages in the lumen of the alveoli and intrabepticular septum. The most common etiologic factor is exposure to tobacco smoke. Our patient, non-smoker, was finally diagnosed after lung biopsy and histopathological evaluation. The gradual clinical improvement after mesalazine was an additional factor confirming the etiology of the disease. This side effect of mesalazine is not common but it should be considered in all patient treated with 5-aminosalicylic acid.

show abstract

Pulmonary manifestations of inflammatory bowel disease

Cited by 62 publications

References 121 publications

Pulmonary Alveolar Proteinosis with Ulcerative Colitis

Pulmonary Alveolar Proteinosis with Ulcerative Colitis

A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα

Pulmonary Manifestations of Crohn’s Disease or Chronic Pharmacotherapy Complications? – Case Report

Contact Info

Product

Resources

About